In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-β-lactamase-producing Pseudomonas aeruginosa

BMC Infectious Diseases

Volumn 9, Issue , 2009, Pages

  Oie, Shigeharu ^a   Fukui, Yumi ^a   Yamamoto, Masaya ^a   Masuda, Yuki ^a   Kamiya, Akira ^a  

^a YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; HABEKACIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; ANTIINFECTIVE AGENT; BETA LACTAMASE;

AGAR DILUTION; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG SCREENING; IN VITRO STUDY; JAPAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; ENZYMOLOGY; METABOLISM; MICROBIOLOGICAL EXAMINATION;

AMIKACIN; ANTI-BACTERIAL AGENTS; AZTREONAM; BETA-LACTAMASES; CEFTAZIDIME; COLISTIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 70049092358     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-9-123     Document Type: Article

References (32)

1. Thuong M Arvanite K Ruimy R Salmonière P Scanvic-Hameg A Lucet JC Régnier B Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit J Hosp Infect 2003, 53:274-282 10.1053/jhin.2002.1370 12660124
2. Lockhart SR Abramson MA Beekmann SE Gallagher G Riedel S Diekema DJ Quinn JP Doern GV Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004 J Clin Microbiol 2007, 45:3352-3359 2045364 17715376 10.1128/JCM.01284-07
3. Rossolini GM Mantengoli E Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa Clin Microbiol Infect 2005, 11:17-32 10.1111/j.1469-0691.2005.01161.x 15953020
4. Karlowsky JA Draghi DC Jones ME Thornsberry C Friedland IR Sahm DF Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001 Antimicrob Agents Chemother 2003, 47:1681-1688 153334 12709340 10.1128/AAC.47.5.1681-1688.2003
5. Livermore DM Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin Infect Dis 2002, 34:634-640 10.1086/338782 11823954
6. Garberding J Gaynes R Horan T Abshire J Alonso-Echanove J Edwards J National nosocomial infections surveillance (NNIS) system report, data summary from January 1990-May 1999 (issued June 1999) Am J Infect Control 1999, 27:520-532 10.1016/S0196-6553(99)70031-3 10586157
7. Sofianou D Tsakris A Skoura L Douboyas J Extended high-level cross-resistance to antipseudomonal antibiotics amongst Pseudomonas aeruginosa isolates in a university hospital J Antimicrob Chemother 1998, 40:740-742 10.1093/jac/40.5.740
8. Oie S Uematsu T Sawa A Mizuno H Tomita M Ishida S Okano Y Kamiya A In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa J Antimicrob Chemother 2003, 52:911-914 10.1093/jac/dkg478 14585851
9. Oie S Sawa A Kamiya A Mizuno H In-vitro effects of a combination of antipseudomonal antibiotics against multidrug-resistant Pseudomonas aeruginosa J Antimicrob Chemother 1999, 44:689-691 10.1093/jac/44.5.689 10552987
10. Maeda K Kobayashi Y Oie S Ishida S Okano Y Kobayashi T Shikichi K Mizuno H Kamiya A Antimicrobial effects of drugs against multidrug-resistant Pseudomonas aeruginosa Biol Pharm Bull 2008, 31:1898-1901 10.1248/ bpb.31.1898 18827351
11. Walsh TR Toleman MA Poirel L Nordmann P Metallo-β-lactamases: The quiet before the storm? Clin Microbiol Rev 2005, 18:306-325 1082798 15831827 10.1128/CMR.18.2.306-325.2005
12. Sibata N Doi Y Yamane K Yagi T Kurokawa H Shibayama K Kato H Kai K Arakawa Y PCR typing of genetic determinants for metallo-β-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron J Clin Microbiol 2003, 41:5407-5413 309014 14662918 10.1128/ JCM.41.12.5407-5413.2003
13. Murray BE Singh KV Markowitz SM Lopardo HA Patterson JE Zervos MJ Rubeglio E Eliopoulos GM Rice LB Goldstein FW et al Evidence for clonal spread of a single strain of β-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states J Infect Dis 1991, 163:780-785 1901330
14. National Committee for Clinical Laboratory Standards Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard M7-A2 Villanova, PA: NCCLS 2 1990
15. Soussy CJ Cluzel R Courvalin P Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France Eur J Clin Microbiol Infect Dis 1994, 13:238-246 10.1007/BF01974543 8050437
16. Giamarellos-Bourboulis EJ Kentepozidis N Antonopoulou A Plachouras D Tsaganos T Giamarellou H Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa Diagn Microbiol Infect Dis 2005, 51:113-117 10.1016/j.diagmicrobio.2004.09.004 15698716
17. Rochon-Edouard S Pestel-Caron M Lemeland J-F Caron F In vitro synergic effects of double and triple combinations of β-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains Antimicrob Agents Chemother 2000, 44:3055-3060 101602 11036022 10.1128/AAC.44.11.3055-3060.2000
18. Giamarellos-Bourboulis EJ Grecka P Giamarellou H In-vitro interactions of DX- a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa J Antimicrob Chemother 8739, 38:287-291 10.1093/jac/38.2.287
19. Hallander HO Dornbusch K Gezelius L Jacobson K Karlsson I Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: Interaction index and killing curve method Antimicrob Agents Chemother 1982, 22:743-752 185655 7181485
20. Rasmussen BA Bush K Carbapenem-hydrolyzing β-lactamases Antimicrob Agents Chemother 1997, 41:223-232 163693 9021171
21. Bellais S Mimoz O Léotard S Jacolot A Petitjean O Nordmann P Efficacy of β-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-β-lactamase-producing strain of Pseudomonas aeruginosa Antimicrob Agents Chemother 2002, 46:2032-2034 127240 12019134 10.1128/AAC.46.6.2032-2034.2002
22. Horimoto H Morimoto T Kakimoto S Clinical study of penetration of aztreonam into serum and pleural effusion Chemotherapy (Tokyo) 1993, 41:573-575
23. Mizuta M Linkin DR Nachamkin I Fishman NO Weiner MG Sheridan A Lautenbach E Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: Potential role of a combination antibiogram Infect Control Hosp Epidemiol 2006, 27:413-415 10.1086/503175 16622822
24. Drago L Vecchi ED Nicola L Colombo A Guerra A Gismondo MR Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp Chemotherapy 2004, 50:202-210 10.1159/000081033 15452399
25. Chen YH Peng CF Lu PL Tsai JJ Chen TP In vitro activities of antibiotic combinations against clinical isolates of Pseudomonas aeruginosa Kaohsiung J Med Sci 2004, 20:261-267 10.1016/S1607-551X(09)70116-0 15253466
26. Giamarellos-Bourboulis EJ Grecka P Giamarellou H Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa Diagn Microbiol Infect Dis 1997, 29:81-86 10.1016/S0732-8893(97)00123-5 9368083
27. Gerceker AA Gurler B In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa J Antimicrob Chemother 1995, 36:707-711 10.1093/jac/36.4.707 8591946
28. Berlana D Llop JM Fort E Badia MB Jódar R Use of colistin in the treatment of multiple-drug-resistant gram-negative infections Am J Health-Syst Pharm 2005, 62:39-47 15658071
29. Timurkaynak F Can F Azap ÖK Demirbilek M Arslan H Karaman SO In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units Int J Antimicrob Agents 2006, 27:224-228 10.1016/ j.ijantimicag.2005.10.012 16464562
30. Linden PK Kusne S Coley K Fontes P Kramer DJ Paterson D Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa Clin Infect Dis 2003, 37:e154-60 10.1086/379611 14614688
31. Levin AS Barone AA Penco J Santos MV Marinho IS Arruda EA Manrique EI Costa SF Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii Clin Infect Dis 1999, 28:1008-1011 10.1086/514732 10452626
32. Evans ME Feola DJ Rapp RP Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria Ann Pharmacother 1999, 33:960-967 10.1345/aph.18426 10492501